Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan

Blood

Volumn 96, Issue 9, 2000, Pages 3175-3180

  Rowley, M ^a   Liu, P ^a   Van Ness, B ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; MELPHALAN;

ALLELE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC MANIPULATION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; MYELOMA; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034332169     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3175     Document Type: Article

References (32)

1. Studies on the clonal origin of multiple myeloma: Use of the individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation
2. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
3. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
4. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
5. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266
6. IL-6 and tumor necrosis factor-alpha: Autocrine and paracrine cytokines involved in B cell function
7. Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type p53
8. p53 and ras gene mutations in multiple myeloma
9. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias
10. Repression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene product
11. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF-kappa-B, and Sp1 transcription factors
12. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL-6) activity by p53 species
13. Signaling mechanisms through gp130: A model of the cytokine system
14. Oncogenes in multiple myeloma: Point mutation of N-ras
15. Ras oncogene mutation in multiple myeloma
16. Activating mutations of N- and K-ras in multiple myeloma show distinct clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III trial
17. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin-6-dependent myeloma cell line ANBL6
18. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6
19. Mutations of the p53 gene in human myeloma cell lines
20. Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes
21. Coordinate transcription and V(D)J recombination of the kappa immunoglobulin light-chain locus: NF-kB-dependent and -independent pathways of activation
22. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed paraffin-embedded tissues by PCR
23. Interferon-α protects myeloma cell lines from dexamethasone induced apoptosis
24. p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene
25. p53 and its implication in apoptosis
26. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma: An Eastern Cooperative Oncology Group study
27. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents
28. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells
29. p53 and chemosensitivity
30. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated, or no p53
31. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
32. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells